Broadfin Healthcare Master Fund Ltd, 10% Owner at Recro Pharma, Inc. (REPH), sold 172,208 shares at $9.50 ($1.6M) on 2017-11-21, disclosed to the SEC on 2017-11-24.
Open-market sale of $1.6M REPH by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.37 | 2,440 | $23K | 1.4% |
| 2 | $9.50 | 100,000 | $950K | 58.4% |
| 3 | $9.36 | 3,088 | $29K | 1.8% |
| 4 | $9.37 | 48,566 | $455K | 28.0% |
| 5 | $9.31 | 2,051 | $19K | 1.2% |
| 6 | $9.32 | 2,913 |
| $27K |
| 1.7% |
| 7 | $9.37 | 5,900 | $55K | 3.4% |
| 8 | $9.39 | 5,800 | $54K | 3.3% |
| 9 | $9.48 | 1,450 | $14K | 0.8% |
| Total | $9.45 avg | 172,208 | $1.6M | 100% |
| Filing → |
| REPH | SELL | 2017-12-14 | $1.5M | — | Filing → |
| REPH | SELL | 2017-12-07 | $1.0M | — | Filing → |
| PETX | SELL | 2017-12-01 | $5.1M | — | Filing → |